Updates Guidance to Reflect Pending Magellan Complete Care Divestiture
PHOENIX–(BUSINESS WIRE)–Magellan Health, Inc. (NASDAQ: MGLN) today announced financial results for the second quarter ended June 30, 2020, as summarized below:
| Three Months Ended | Six Months Ended | |||||||||||||
| June 30 | June 30 | |||||||||||||
| (In millions, except per share amounts) | ||||||||||||||
| Continuing Operations |
|
2020 |
|
2019 |
Chg |
|
|
2020 |
|
2019 |
|
Chg |
||
| Net revenue |
$ |
1,100.1 |
$ |
1,154. (Read more…)3 |
-4.7 |
% |
$ |
2,222.5 |
$ |
2,273.3 |
|
-2.2 |
% |
|
| Net income (loss) |
$ |
47.1 |
$ |
7.2 |
552.9 |
% |
$ |
46.0 |
$ |
(1.0 |
) |
NM |
|
|
| Segment profit [1] |
$ |
57.0 |
$ |
53.6 |
6.4 |
% |
$ |
98.6 |
$ |
84.3 |
|
17.0 |
% |
|
| Adjusted net income [1] |
$ |
21.3 |
$ |
12.9 |
64.7 |
% |
$ |
27.3 |
$ |
10.4 |
|
161.7 |
% |
|
| Earnings (loss) per share |
$ |
1.86 |
$ |
0.30 |
520.0 |
% |
$ |
1.84 |
$ |
(0.04 |
) |
NM |
|
|
| Adjusted earnings per share [1] |
$ |
0.84 |
$ |
0.53 |
58.5 |
% |
$ |
1.09 |
$ |
0.43 |
|
153.5 |
% |
|
| [1] Refer to the Basis of Presentation for a discussion of non-GAAP financial measures. |
| NM means not meaningful. |
Magellan Complete Care Business Reflected as Discontinued Operations
As previously announced, on April 30, 2020, the Company and Molina Healthcare, Inc. (Molina) entered into a Stock and Asset Purchase Agreement in which the Company has agreed to sell its Magellan Complete Care (MCC) business to Molina. Therefore, the consolidated financial statements for all periods presented now reflect the MCC business as discontinued operations. In addition, the Company’s updated 2020 guidance now reflects its continuing operations, thereby excluding the MCC business from guidance for the full fiscal year 2020.
Second Quarter 2020 Highlights (all percentage changes compare second quarter 2020 to second quarter 2019 for continuing operations unless otherwise noted):
- Net revenue decreased 4.7 percent to $1.1 billion.
- Net income increased 552.9 percent to $47.1 million.
- Segment profit increased 6.4 percent to $57.0 million.
- Adjusted net income increased 64.7 percent to $21.3 million.
- Unrestricted cash and investments were $161.5 million as of June 30, 2020. Approximately $29 million of the unrestricted cash and investments at June 30, 2020 is related to excess capital and undistributed earnings held at regulated entities of continuing operations. In addition, the Company had approximately $160 million of excess capital and undistributed earnings held at regulated entities of discontinued operations at June 30, 2020.
- On June 24, 2020, the Company announced the election of Christopher J. Chen, M.D., and Mural R. (Joe) Josephson to Magellan’s board of directors at the 2020 Annual Meeting of Stockholders.
- On June 16, 2020, the Company announced the appointment of Dr. Caroline Carney as the chief medical officer.
- On July 6, 2020, the Company announced the appointment of Darren Lehrich as the chief investor relations officer.
“Throughout the COVID-19 pandemic, I continue to be inspired by the dedication and resilience of our organization,” said Kenneth Fasola, chief executive officer, Magellan Health.
“As we look to the balance of 2020, our strategic priorities remain intact. We are resolute in delivering on our existing commitments, lowering our operating cost structure, strengthening our capabilities through innovation, and improving our ability to capitalize on growth opportunities. The culmination of these efforts will strengthen our competitive position and lead to stronger growth in the future,” continued Fasola.
Net Revenue
Net revenue for the second quarter of 2020, was $1.1 billion, representing a 4.7 percent decrease from the second quarter of 2019. This decrease was largely attributable to net contract losses within the healthcare segment.
Segment Profit
Segment profit was $57.0 million for the second quarter, compared to $53.6 million in the second quarter of 2019.
- Healthcare segment profit was $60.8 million, representing an increase of $19.7 million from the second quarter of 2019. This year-over-year increase was primarily driven by lower utilization trends in the specialty healthcare reporting unit due to COVID-19.
- Pharmacy Management segment profit was $13.2 million, representing a decrease of $17.6 million from the second quarter of 2019. This year-over-year decrease was primarily driven by losses in the Medicare Part D business, customer settlements related to prior periods, and start-up costs associated with the Medi-Cal contract implementation.
- Corporate costs inclusive of eliminations, but excluding stock compensation expense, totaled $17.1 million, as compared to $18.3 million in the second quarter of 2019.
Other Items
The Company recorded a $38.9 million income tax benefit during the second quarter of 2020 associated with deferred tax assets in connection with the pending divestiture of MCC to Molina. The Company recorded a special charge of $8.3 million during the second quarter of 2020 associated with lease terminations and abandonments related to planned reductions to the Company’s real estate footprint. The non-recurring tax benefit and the special charge are reflected as reconciling items for the adjusted net income calculation.
Income from discontinued operations, net of tax, for the second quarter of 2020 was $36.4 million, as compared to $6.4 million during the second quarter of 2019. This improvement was primarily driven by lower utilization trends due to COVID-19.
Cash Flow & Balance Sheet
Cash flow used in operations for the six months ended June 30, 2020, was $7.5 million, as compared to cash provided by operations of $45.9 million for the six months ended June 30, 2019. The year over year change is primarily attributable to timing of accounts receivable and other working capital.
As of June 30, 2020, the Company’s unrestricted cash and investments totaled $161.5 million, an increase of $80.5 million from the balance at December 31, 2019. Approximately $29 million of the unrestricted cash and investments at June 30, 2020 is related to excess capital and undistributed earnings held at regulated entities of continuing operations. In addition, the Company had approximately $160 million of excess capital and undistributed earnings held at regulated entities of discontinued operations at June 30, 2020. At June 30, 2020, the Company had $320 million of undrawn capacity on the Company’s $400 million revolving credit facility.
“We were pleased with solid second quarter results, and believe our key initiatives for the balance of 2020 should establish a stronger foundation for future growth. We will also have significant financial flexibility to add shareholder value following the completion of the MCC sale, and we will remain disciplined as we evaluate opportunities to deploy capital,” said Jonathan N. Rubin, chief financial officer, Magellan Health.
Updated 2020 Guidance
The Company announced its updated 2020 fiscal year guidance parameters for continuing operations. This updated guidance excludes the MCC business, which is now reflected as discontinued operations retrospective to January 1, 2020.
| Updated 2020 Guidance | |||||||
| (In millions, except per share results) | Low | High | |||||
| Net revenue |
$ |
4,400.0 |
|
$ |
4,600.0 |
|
|
| Income (loss) before income taxes |
$ |
(22.0 |
) |
$ |
(2.0 |
) |
|
| Net income |
$ |
15.0 |
|
$ |
27.0 |
|
|
| Segment Profit[1] |
$ |
145.0 |
|
$ |
165.0 |
|
|
| Adjusted net income[1] |
$ |
16.0 |
|
$ |
28.0 |
|
|
| Diluted per share results: | |||||||
| Earnings per share[2] |
$ |
0.59 |
|
$ |
1.06 |
|
|
| Adjusted earnings per share[1][2] |
$ |
0.63 |
|
$ |
1.10 |
|
|
| [1] Refer to the Basis of Presentation for a discussion of non-GAAP financial measures. | ||||||
| [2] 2020 EPS and Adjusted EPS guidance includes share repurchases and option exercises through the close of business July 24, 2020, but excludes the impact of any potential future activity. Based on average fully diluted shares of 25.4 million. |
The Company expects net revenue in the range of $4.4 billion to $4.6 billion. Net income is expected to be in the range of $15 million to $27 million, which equates to a diluted earnings per share range of $0.59 to $1.06. Adjusted net income is expected to be in the range of $16 million to $28 million, which equates to an adjusted EPS range of $0.63 to $1.10. Segment profit for the full year 2020 is expected to be in the range of $145 million to $165 million. This updated segment profit guidance includes $25 million to $30 million of stranded overhead costs that were previously allocated to the MCC business, but are required to be reclassified to continuing operations in accordance with GAAP. Following the closing of the MCC transaction, the Company expects approximately half of the stranded overhead costs to be mitigated through planned cost reductions, while the remaining amount is expected to be largely offset in 2021 by payments under a transition services agreement with Molina.
Earnings Conference Call
Management will discuss the Company’s second quarter 2020 results on a conference call scheduled for Wednesday, July 29, 2020 at 9:30 a.m. Eastern. The conference call may be accessed by dialing (877) 269-7756 (Domestic) and (201) 689-7817 (International) using conference ID code 13707398. A telephonic replay will be available shortly after the conclusion of the call through August 28, 2020. This replay may be accessed by dialing (877) 660-6853 (Domestic) or (201) 612-7415 (International) using the same conference ID code. The conference call will also be available live via webcast at Magellan’s investor relations page at MagellanHealth.com. A replay of the webcast will also be available at the site listed above for 30 days, beginning approximately two hours after its conclusion.
Basis of Presentation
In addition to results determined under Generally Accepted Accounting Principles (GAAP), Magellan provides certain non-GAAP financial measures that management believes are useful in assessing the Company’s performance. Following is a description of these important non-GAAP measures.
Segment profit is equal to net revenue less the sum of cost of care, cost of goods sold, direct service costs and other operating expenses, and includes income from unconsolidated subsidiaries, but excludes segment profit or loss from non-controlling interests held by other parties, stock compensation expense, special charges or benefits, as well as changes in the fair value of contingent consideration recorded in relation to acquisitions.
Adjusted net income and adjusted earnings per share reflect certain adjustments made for acquisitions completed after January 1, 2013, to exclude non‑cash stock compensation expense resulting from restricted stock purchases by sellers, changes in the fair value of contingent consideration, amortization of identified acquisition intangibles, as well as impairment of identified acquisition intangibles, special charges, and any impact related to the sale of MCC.
Included in the tables issued with this press release are the reconciliations from GAAP measures to the corresponding non-GAAP measures.
About Magellan Health: Magellan Health, Inc., a Fortune 500 company, is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan’s customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. For more information, visit MagellanHealth.com.
Forward-Looking Statements
This press release, and oral statements made in connection with this release, include statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, express or implied forward-looking statements relating to 2020 guidance for net revenue, income (loss) before income taxes, net income, segment profit, adjusted net income, earnings per share and adjusted earnings per share; growth and margin opportunities and initiatives; business environment, long term opportunities and strategy; transformation, process improvement and innovation initiatives; new product offerings, digital tools and advanced analytics capabilities; our expectations regarding the benefits to the Company of the transaction to sell the Magellan Complete Care business (the “transaction”), the ability of the Company to obtain regulatory approvals for the transaction and to satisfy other closing conditions, the anticipated timing of the closing of the transaction, the benefits to the Company of the commercial agreements entered into in connection with the transaction, the ability of the Company to use the proceeds of the transaction to fund future growth initiatives or otherwise create value for the Company, the ability of the Company to offset stranded overhead costs associated with the transaction, the ability of the Company to strategically focus on enhancing its behavioral and specialty health business, as well as the continued growth of its pharmacy business, and the ability of the Company to achieve our strategic and growth goals. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Factors that could cause actual results to differ materially from those expressed or implied include the effectiveness of business continuity plans during, and the risks associated with, the COVID-19 pandemic; termination or non-renewal of customer contracts; changes in rates paid to and/or by the Company by customers and/or providers; our ability to develop and maintain satisfactory relationships with providers; higher utilization of healthcare services by the Company’s members; risks and uncertainties associated with the pharmacy benefits management industry; costs to maintain or upgrade our information technology and other business systems and the effectiveness and security of such systems; cyberattacks, other privacy/data security incidents, and/or our failure to comply with related regulations; delays, higher costs or inability to implement new business or other Company initiatives; the impact of changes in the contracting model for Medicaid contracts; impairment of our goodwill and intangible assets; the impact of new or amended laws or regulations; costs and other liabilities associated with litigation, government investigations, audits or reviews; competition; operational issues; healthcare reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, to be filed with the Securities and Exchange Commission later today, and subsequent reports on Forms 10-Q and 8-K. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | ||||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||||
| (Unaudited) | ||||||||||
| (In thousands) | ||||||||||
| December 31, 2019 | June 30, 2020 | |||||||||
| ASSETS | ||||||||||
| Current Assets: | ||||||||||
| Cash and cash equivalents |
$ |
115,752 |
|
$ |
160,419 |
|
||||
| Accounts receivable, net |
|
680,569 |
|
|
753,065 |
|
||||
| Short-term investments |
|
98,797 |
|
|
75,671 |
|
||||
| Pharmaceutical inventory |
|
44,962 |
|
|
36,694 |
|
||||
| Other current assets |
|
69,687 |
|
|
80,375 |
|
||||
| Current portion of assets held for sale |
|
663,276 |
|
|
1,145,904 |
|
||||
| Total Current Assets |
|
1,673,043 |
|
|
2,252,128 |
|
||||
| Property and equipment, net |
|
131,712 |
|
|
141,035 |
|
||||
| Long-term investments |
|
2,864 |
|
|
– |
|
||||
| Deferred income taxes |
|
1,840 |
|
|
28,519 |
|
||||
| Other long-term assets |
|
58,905 |
|
|
60,770 |
|
||||
| Goodwill |
|
806,421 |
|
|
806,421 |
|
||||
| Other intangible assets, net |
|
81,675 |
|
|
62,330 |
|
||||
| Assets held for sale, less current portion |
|
335,713 |
|
|
– |
|
||||
| Total Assets |
$ |
3,092,173 |
|
$ |
3,351,203 |
|
||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||
| Current Liabilities: | ||||||||||
| Accounts payable |
$ |
83,790 |
|
$ |
99,199 |
|
||||
| Accrued liabilities |
|
191,854 |
|
|
187,286 |
|
||||
| Medical claims payable |
|
128,114 |
|
|
112,077 |
|
||||
| Other medical liabilities |
|
92,915 |
|
|
110,268 |
|
||||
| Current debt, finance lease and deferred financing obligations |
|
3,491 |
|
|
84,942 |
|
||||
| Current portion of liabilities held for sale |
|
409,983 |
|
|
504,459 |
|
||||
| Total Current Liabilities |
|
910,147 |
|
|
1,098,231 |
|
||||
| Long-term debt, finance lease and deferred financing obligations |
|
679,125 |
|
|
641,950 |
|
||||
| Deferred income taxes |
|
1,971 |
|
|
– |
|
||||
| Tax contingencies |
|
9,453 |
|
|
11,097 |
|
||||
| Deferred credits and other long-term liabilities |
|
56,393 |
|
|
56,956 |
|
||||
| Liabilities held for sale, less current portion |
|
37,301 |
|
|
– |
|
||||
| Total Liabilities |
|
1,694,390 |
|
|
1,808,234 |
|
||||
| Stockholders’ Equity: | ||||||||||
| Ordinary common stock |
|
543 |
|
|
550 |
|
||||
| Additional paid-in capital |
|
1,386,616 |
|
|
1,429,995 |
|
||||
| Retained earnings |
|
1,475,207 |
|
|
1,576,549 |
|
||||
| Accumulated other comprehensive income |
|
144 |
|
|
602 |
|
||||
| Ordinary common stock in treasury, at cost |
|
(1,464,727 |
) |
|
(1,464,727 |
) |
||||
| Total Stockholders’ Equity |
|
1,397,783 |
|
|
1,542,969 |
|
||||
| Total Liabilities and Stockholders’ Equity |
$ |
3,092,173 |
|
$ |
3,351,203 |
|
||||
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | ||||||||||||||||||
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | ||||||||||||||||||
| (Unaudited) | ||||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||||
|
Three Months Ended |
|
Six Months Ended |
||||||||||||||||
|
June 30, |
|
June 30, |
||||||||||||||||
|
2019 |
|
|
2020 |
|
2019 |
|
|
2020 |
||||||||||
| Net revenue: | ||||||||||||||||||
| Managed care and other |
$ |
608,614 |
|
$ |
548,711 |
|
$ |
1,175,162 |
|
$ |
1,101,879 |
|
||||||
| PBM |
|
545,675 |
|
|
551,364 |
|
|
1,098,133 |
|
|
1,120,575 |
|
||||||
| Total net revenue |
|
1,154,289 |
|
|
1,100,075 |
|
|
2,273,295 |
|
|
2,222,454 |
|
||||||
| Costs and expenses: | ||||||||||||||||||
| Cost of care |
|
408,911 |
|
|
321,831 |
|
|
778,008 |
|
|
670,939 |
|
||||||
| Cost of goods sold |
|
501,081 |
|
|
528,067 |
|
|
1,027,395 |
|
|
1,061,308 |
|
||||||
| Direct service costs and other operating expenses (1) |
|
195,907 |
|
|
199,756 |
|
|
398,207 |
|
|
403,997 |
|
||||||
| Depreciation and amortization |
|
28,191 |
|
|
23,888 |
|
|
53,608 |
|
|
47,246 |
|
||||||
| Interest expense |
|
9,070 |
|
|
7,995 |
|
|
18,107 |
|
|
16,953 |
|
||||||
| Interest and other income |
|
(1,821 |
) |
|
(551 |
) |
|
(3,580 |
) |
|
(1,770 |
) |
||||||
| Special charges |
|
– |
|
|
8,309 |
|
|
– |
|
|
8,309 |
|
||||||
| Total costs and expenses |
|
1,141,339 |
|
|
1,089,295 |
|
|
2,271,745 |
|
|
2,206,982 |
|
||||||
| Income from continuing operations before income taxes |
|
12,950 |
|
|
10,780 |
|
|
1,550 |
|
|
15,472 |
|
||||||
| Provision (benefit) for income taxes |
|
5,735 |
|
|
(36,328 |
) |
|
2,526 |
|
|
(30,566 |
) |
||||||
| Net income (loss) from continuing operations |
|
7,215 |
|
|
47,108 |
|
|
(976 |
) |
|
46,038 |
|
||||||
| Income from discontinued operations, net of tax |
|
6,398 |
|
|
36,397 |
|
|
15,020 |
|
|
55,717 |
|
||||||
| Net Income |
$ |
13,613 |
|
$ |
83,505 |
|
$ |
14,044 |
|
$ |
101,755 |
|
||||||
| Weighted average number of common shares outstanding — basic |
|
24,101 |
|
|
25,054 |
|
|
24,024 |
|
|
24,891 |
|
||||||
| Weighted average number of common shares outstanding — diluted |
|
24,416 |
|
|
25,278 |
|
|
24,315 |
|
|
25,074 |
|
||||||
| Net income (loss) per common share — basic | ||||||||||||||||||
| Continuing operations |
$ |
0.30 |
|
$ |
1.88 |
|
$ |
(0.04 |
) |
$ |
1.85 |
|
||||||
| Discountinued operations |
|
0.26 |
|
|
1.45 |
|
|
0.62 |
|
|
2.24 |
|
||||||
| Consolidated operations |
$ |
0.56 |
|
$ |
3.33 |
|
$ |
0.58 |
|
$ |
4.09 |
|
||||||
| Net income (loss) per common share — diluted | ||||||||||||||||||
| Continuing operations |
$ |
0.30 |
|
$ |
1.86 |
|
$ |
(0.04 |
) |
$ |
1.84 |
|
||||||
| Discountinued operations |
|
0.26 |
|
|
1.44 |
|
|
0.62 |
|
|
2.22 |
|
||||||
| Consolidated operations |
$ |
0.56 |
|
$ |
3.30 |
|
$ |
0.58 |
|
$ |
4.06 |
|
||||||
| Net income |
$ |
13,613 |
|
$ |
83,505 |
|
$ |
14,044 |
|
$ |
101,755 |
|
||||||
| Other comprehensive income: | ||||||||||||||||||
| Unrealized gains on available-for-sale securities (2) |
|
419 |
|
|
659 |
|
|
739 |
|
|
458 |
|
||||||
| Comprehensive income |
$ |
14,032 |
|
$ |
84,164 |
|
$ |
14,783 |
|
$ |
102,213 |
|
||||||
| (1) Includes stock compensation expense of $5,207 and $6,592 for the three months ended June 30, 2019 and 2020, respectively, and $14,607 and $12,389 for the six months ended June 30, 2019 and 2020, respectively. | ||||||||||
| (2) Net of income tax provision of $131 and $219 for the three months ended June 30, 2019 and 2020, respectively, and $231 and $152 for the six months ended June 30, 2019 and 2020, respectively. | ||||||||||
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||
| (Unaudited) | |||||||||
| (In thousands) | |||||||||
|
Six Months Ended |
|||||||||
|
June 30, |
|||||||||
|
2019 |
|
|
2020 |
||||||
| Cash flows from operating activities: | |||||||||
| Net income |
$ |
14,044 |
|
$ |
101,755 |
|
|||
| Adjustments to reconcile net income to net cash from operating activities: | |||||||||
| Depreciation and amortization |
|
64,198 |
|
|
57,951 |
|
|||
| Special charges |
|
– |
|
|
8,309 |
|
|||
| Non-cash interest expense |
|
679 |
|
|
941 |
|
|||
| Non-cash stock compensation expense |
|
15,021 |
|
|
13,015 |
|
|||
| Non-cash income tax provision (benefit) |
|
1,026 |
|
|
(29,443 |
) |
|||
| Non-cash (amortization) accretion on investments |
|
(327 |
) |
|
907 |
|
|||
| Changes in assets and liabilities, net of effects from acquisitions of businesses: | |||||||||
| Accounts receivable, net |
|
(51,544 |
) |
|
(24,535 |
) |
|||
| Pharmaceutical inventory |
|
(4,793 |
) |
|
8,268 |
|
|||
| Other assets |
|
(23,890 |
) |
|
(38,322 |
) |
|||
| Accounts payable and accrued liabilities |
|
20,821 |
|
|
62,970 |
|
|||
| Medical claims payable and other medical liabilities |
|
4,329 |
|
|
10,510 |
|
|||
| Contingent consideration |
|
(3,758 |
) |
|
– |
|
|||
| Tax contingencies |
|
610 |
|
|
1,343 |
|
|||
| Deferred credits and other long-term liabilities |
|
(7,429 |
) |
|
(2,537 |
) |
|||
| Other |
|
372 |
|
|
(289 |
) |
|||
| Net cash provided by operating activities |
|
29,359 |
|
|
170,843 |
|
|||
| Net cash (used in) provided by operating activities from discontinued operations |
|
(16,574 |
) |
|
178,326 |
|
|||
| Net cash provided by (used in) operating activities from continuing operations |
|
45,933 |
|
|
(7,483 |
) |
|||
| Cash flows from investing activities: | |||||||||
| Capital expenditures |
|
(27,804 |
) |
|
(38,305 |
) |
|||
| Acquisitions and investments in businesses, net of cash acquired |
|
(320 |
) |
|
(369 |
) |
|||
| Purchases of investments |
|
(295,768 |
) |
|
(417,688 |
) |
|||
| Proceeds from maturities and sales of investments |
|
288,290 |
|
|
288,137 |
|
|||
| Net cash used in investing activities |
|
(35,602 |
) |
|
(168,225 |
) |
|||
| Net cash used in investing activities from discontinued operations |
|
(3,210 |
) |
|
(156,800 |
) |
|||
| Net cash used in investing activities from continuing operations |
|
(32,392 |
) |
|
(11,425 |
) |
|||
| Cash flows from financing activities: | |||||||||
| Proceeds from borrowings on revolving line of credit |
|
– |
|
|
80,000 |
|
|||
| Payments to acquire treasury stock |
|
(4,124 |
) |
|
– |
|
|||
| Proceeds from exercise of stock options |
|
20,647 |
|
|
29,825 |
|
|||
| Payments on debt, finance lease and deferred financing obligations |
|
(15,543 |
) |
|
(40,264 |
) |
|||
| Payments on contingent consideration |
|
(6,247 |
) |
|
– |
|
|||
| Other |
|
(446 |
) |
|
(1,136 |
) |
|||
| Net cash (used in) provided by financing activities |
|
(5,713 |
) |
|
68,425 |
|
|||
| Net cash provided by financing activities from discontinued operations |
|
– |
|
|
4,850 |
|
|||
| Net cash (used in) provided by financing activities from continuing operations |
|
(5,713 |
) |
|
63,575 |
|
|||
| Net increase in cash and cash equivalents |
|
7,828 |
|
|
44,667 |
|
|||
| Cash and cash equivalents at beginning of period |
|
86,923 |
|
|
115,752 |
|
|||
| Cash and cash equivalents at end of period |
$ |
94,751 |
|
$ |
160,419 |
|
|||
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | ||||||||||||||||||
| CONTINUING OPERATIONS RESULTS BY BUSINESS SEGMENT | ||||||||||||||||||
| (Unaudited) | ||||||||||||||||||
| (In thousands) | ||||||||||||||||||
|
Three Months Ended |
|
Six Months Ended |
||||||||||||||||
|
June 30, |
|
June 30, |
||||||||||||||||
|
2019 |
|
|
2020 |
|
2019 |
|
|
2020 |
||||||||||
| Healthcare | ||||||||||||||||||
| Managed care and other revenue |
$ |
546,113 |
|
$ |
481,021 |
|
$ |
1,052,935 |
|
$ |
969,927 |
|
||||||
| Cost of care |
|
(408,911 |
) |
|
(321,831 |
) |
|
(778,008 |
) |
|
(670,939 |
) |
||||||
| Direct service costs and other |
|
(98,314 |
) |
|
(100,450 |
) |
|
(198,424 |
) |
|
(206,386 |
) |
||||||
| Stock compensation expense (1) |
|
2,237 |
|
|
2,102 |
|
|
3,780 |
|
|
3,863 |
|
||||||
| Healthcare segment profit |
|
41,125 |
|
|
60,842 |
|
|
80,283 |
|
|
96,465 |
|
||||||
| Pharmacy Management | ||||||||||||||||||
| Managed care and other revenue |
|
62,648 |
|
|
67,867 |
|
|
122,543 |
|
|
132,302 |
|
||||||
| PBM revenue |
|
550,010 |
|
|
556,195 |
|
|
1,106,575 |
|
|
1,129,973 |
|
||||||
| Cost of goods sold |
|
(505,203 |
) |
|
(532,685 |
) |
|
(1,035,410 |
) |
|
(1,070,259 |
) |
||||||
| Direct service costs and other |
|
(78,776 |
) |
|
(80,082 |
) |
|
(158,411 |
) |
|
(161,948 |
) |
||||||
| Stock compensation expense (1) |
|
2,124 |
|
|
1,939 |
|
|
3,796 |
|
|
4,046 |
|
||||||
| Pharmacy Management segment profit |
|
30,803 |
|
|
13,234 |
|
|
39,093 |
|
|
34,114 |
|
||||||
| Corporate and Elimination (2) | ||||||||||||||||||
| Managed care and other revenue |
|
(147 |
) |
|
(177 |
) |
|
(316 |
) |
|
(350 |
) |
||||||
| PBM revenue |
|
(4,335 |
) |
|
(4,831 |
) |
|
(8,442 |
) |
|
(9,398 |
) |
||||||
| Cost of goods sold |
|
4,122 |
|
|
4,618 |
|
|
8,015 |
|
|
8,951 |
|
||||||
| Direct service costs and other |
|
(18,817 |
) |
|
(19,224 |
) |
|
(41,372 |
) |
|
(35,663 |
) |
||||||
| Stock compensation expense (1) |
|
846 |
|
|
2,551 |
|
|
7,031 |
|
|
4,480 |
|
||||||
| Corporate and Elimination |
|
(18,331 |
) |
|
(17,063 |
) |
|
(35,084 |
) |
|
(31,980 |
) |
||||||
| Consolidated | ||||||||||||||||||
| Managed care and other revenue |
|
608,614 |
|
|
548,711 |
|
|
1,175,162 |
|
|
1,101,879 |
|
||||||
| PBM revenue |
|
545,675 |
|
|
551,364 |
|
|
1,098,133 |
|
|
1,120,575 |
|
||||||
| Cost of care |
|
(408,911 |
) |
|
(321,831 |
) |
|
(778,008 |
) |
|
(670,939 |
) |
||||||
| Cost of goods sold |
|
(501,081 |
) |
|
(528,067 |
) |
|
(1,027,395 |
) |
|
(1,061,308 |
) |
||||||
| Direct service costs and other |
|
(195,907 |
) |
|
(199,756 |
) |
|
(398,207 |
) |
|
(403,997 |
) |
||||||
| Stock compensation expense (1) |
|
5,207 |
|
|
6,592 |
|
|
14,607 |
|
|
12,389 |
|
||||||
| Segment profit from continuing operations |
$ |
53,597 |
|
$ |
57,013 |
|
$ |
84,292 |
|
$ |
98,599 |
|
||||||
| Reconciliation of income from continuing before income taxes (GAAP) to segment profit (non-GAAP): | ||||||||||||||||||
| Income from continuing operations before income taxes |
$ |
12,950 |
|
$ |
10,780 |
|
$ |
1,550 |
|
$ |
15,472 |
|
||||||
| Stock compensation expense |
|
5,207 |
|
|
6,592 |
|
|
14,607 |
|
|
12,389 |
|
||||||
| Depreciation and amortization |
|
28,191 |
|
|
23,888 |
|
|
53,608 |
|
|
47,246 |
|
||||||
| Interest expense |
|
9,070 |
|
|
7,995 |
|
|
18,107 |
|
|
16,953 |
|
||||||
| Interest and other income |
|
(1,821 |
) |
|
(551 |
) |
|
(3,580 |
) |
|
(1,770 |
) |
||||||
| Special charges |
|
– |
|
|
8,309 |
|
|
– |
|
|
8,309 |
|
||||||
| Segment profit from continuing operations |
$ |
53,597 |
|
$ |
57,013 |
|
$ |
84,292 |
|
$ |
98,599 |
|
||||||
Contacts
Media Contact: Lilly Ackley, ackleyl@magellanhealth.com, (860) 507-1923
Investor Contact: Darren Lehrich, lehrichd@magellanhealth.com, (860) 507-1814